Sandy davies (76 résultats)

Etat : very_good.

Paperback. Etat : Very Good. No Jacket. May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less.

Etat : Very Good. Former library copy. Pages intact with possible writing/highlighting. Binding strong with minor wear. Dust jackets/supplements may not be included. Includes library markings. Stock photo provided. Product includes identifying sticker. Better World Books: Buy Books. Do Good.

Etat : Good. Your purchase helps support Sri Lankan Children's Charity 'The Rainbow Centre'. Ex-library, so some stamps and wear, but in good overall condition. May contain underlining and/or highlighting. Our donations to The Rainbow Centre have helped provide an education and a safe haven to hundreds of children who live in appalling conditions.…

Etat : Used: Very Good. VERY GOOD CLEAN COPY SENT NEXT WORKING DAY FROM THE U/K 1ST CLASS 0.0.

Hardcover. Etat : Good. Good - Bumped and creased book with tears to the extremities, but not affecting the text block, may have remainder mark or previous owner's name - GOOD Standard-sized.

Etat : New.

Paperback or Softback. Etat : New. Harsh Punishment: The Burning of the Charlestown Convent, 1834. Book.

Etat : As New. Unread book in perfect condition.

Hardcover. Etat : Used - Very Good. Captured through the lenses of some of the leading names in contemporary photography, 'Cities on the Edge' provides a fascinating glimpse into six of the world's 'edgiest' cities--Liverpool, Naples, Marseilles, Istanbul, Gdansk, and Bremen. Published to coincide with an ambitious 'Cities on the Edge' cultural program, this volume offers an incredible visual journey through six port cities that share common historical, cultural, social, and economic ties. Beautiful, unnerving, often stark but always striking, 'Cities on the Edge' is a stunning tale of six distinct and contradictory cities, whose complicated histories are considered in context with their place in the New Europe.…

Etat : Very Good.

Etat : As New. Unread book in perfect condition.

Paperback. Etat : Brand New. 326 pages. 9.00x6.00x1.00 inches. In Stock.

Etat : New.

paperback. Etat : New. In shrink wrap. Looks like an interesting title.

Etat : New. pp. 120.

Etat : New. pp. 120 2019th edition NO-PA16APR2015-KAP.

Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - This book aims to educate nurses and advanced practice providers (APP's) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP's are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents.Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers.To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP's with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the nextlevel of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations.With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.…

Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - This book aims to educate nurses and advanced practice providers (APP's) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP's are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents.Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers.To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP's with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the nextlevel of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations.With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.…

Taschenbuch. Etat : Neu. Neuware - While the number of incarcerated women is dramatically escalating, women prisoners throughout the world are largely an invisible and neglected population. These comparative essays examine thoroughly the unique problems, challenges, and issues facing women inmates in the United States, Canada, England, New Zealand, Poland, and Thailand. The insightful volume fills a major gap in criminal justice literature, and it provides a solid basis for further discussion of the too-long ignored subject of women's imprisonment.…

Etat : New. KlappentextrnrnA pioneering collection of personal accounts from criminal justice scholars, practitioners, and activists, and from current and former prisoners themselves.

Taschenbuch. Etat : Neu. Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners | Marianne Davies (u. a.) | Taschenbuch | v | Englisch | 2020 | Springer | EAN 9783030165529 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. …

Paperback / softback. Etat : New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days. Quigley, Sandy; Reimann, Kim (illustrateur).

Etat : Hervorragend. Zustand: Hervorragend | Sprache: Englisch | Produktart: Bücher | This book aims to educate nurses and advanced practice providers (APP¿s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP¿s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP¿s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the nextlevel of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.…

Etat : As New. Unread book in perfect condition.

Etat : As New. Unread book in perfect condition.

Etat : New.

Etat : New.

Etat : As New. Unread book in perfect condition.

Etat : As New. Unread book in perfect condition.